Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (443)	1/15/1999 7:26:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

There isn't alot in that patent that I can understand ...but I would suggest that other biotech newbies go down halfway into the patent and read... III. Use of the Hybrid Viruses in Gene Therapy. (I like this part...) One of skill in the art can generate any number of other gene transfer vehicles by including a selected transgene for the treatment of other disorders and here the first paragraph from section four... IV. High Efficiency Production of rAAV The hybrid vectors and conjugates of this invention have another desirable utility in the production of large quantities of recombinant AAV particles. Due to the complicated current methods for generating AAV, there is only a limited amount of AAV available for use in industrial, medical and academic biotechnology procedures. The vectors of the present invention provide a convenient and efficient method for generating large quantities of rAAV particles. Was it already stated on this thread the importance of the little "r"...I am pointing out the right thing? Or was all this hybrid vector talk and recombinant already obvious to you guys? Who besides myself wants to admit they are in over their head and are waiting for one of the biotech gurus to yell eureka! again eom